Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a biotechnology company developing small-molecule molecular glue degraders (MGDs) that use the cell’s own protein-destruction machinery to selectively remove disease-driving proteins. The company’s platform is built around its QuEEN discovery engine and is focused on targets with strong biological and genetic rationale, with research operations in Boston and Basel.

−37,1 %

−31,2 %

+63,5 %

6.12

6.12

— Monte Rosa Therapeutics, Inc.
%
Molecular glue degraders70% Small-molecule therapeutics designed to recruit E3 ligases and degrade disease-relevant proteins.
Discovery platform10% QuEEN-enabled target identification, screening, and rational design capabilities used to generate candidates.
Collaboration revenue20% Revenue from partnered research and licensing arrangements, including the Novartis agreement.

Monte Rosa does not sell to traditional end-market consumers; its direct counterparties are pharmaceutical partners...

  • Pharmaceutical collaboration partnersprimary

    Buy access to Monte Rosa’s discovery platform, target selection, and partnered programs to accelerate drug development.

  • Future commercial patientsprimary

    Would use approved MGD medicines if the company successfully develops and launches products.

  • Healthcare providerssecondary

    Prescribe or administer any approved therapies and influence adoption through treatment protocols.

  • Research and development partnerssecondary

    Engage in co-development or licensing arrangements around specific targets and discovery assets.

Monte Rosa is headquartered in Boston, Massachusetts and maintains research operations in both Boston and Basel,...

  • •Headquartered in Boston, Massachusetts
  • •Research operations in Boston and Basel, Switzerland
  • •Swiss operating subsidiary supports R&D activity
  • •Foreign clinical trials may add regulatory and execution risk
  • •No country-level revenue disclosure was provided

The company’s strategy is to use its QuEEN platform to identify high-confidence targets and build a differentiated...

01
Advance lead MGD programs into the clinicshort-term

Clinical data are needed to validate the platform and create long-term value.

02
Expand and refine the QuEEN discovery enginemedium-term

A stronger platform should improve hit generation, selectivity, and pipeline productivity.

03
Build strategic collaborations and licensing revenuemedium-term

Partnerships can offset R&D spend and validate the technology externally.

Monte Rosa is a pre-commercial biotech, so its value depends heavily on successful preclinical and clinical execution,...

critical

Clinical development failure

Drug candidates may not show sufficient safety or efficacy, which would halt programs and reduce value.

Scope
Lead programs and future pipeline assets
Materiality
high
high

Regulatory approval risk

Even promising candidates may not obtain clearance or marketing approval on time, or at all.

Scope
All product candidates
Materiality
high
high

Financing and liquidity risk

The company expects continued losses and may need additional capital to fund R&D and trials.

Scope
Operating runway and development spend
Materiality
high
medium

Foreign clinical trial execution

Trials outside the U.S. can face protocol adherence issues, administrative burdens, and local political risk.

Scope
International clinical studies
Materiality
medium
medium

Third-party collaboration risk

Partners may be unwilling or unable to meet contractual obligations, affecting revenue and program progress.

Scope
Licensing and collaboration agreements
Materiality
medium
Revenue recognition for collaboration agreements
2025 Novartis Agreement and other licensing/collaboration revenue
Deferred revenue
Reported revenue and balance sheet liabilities
R&D accrual estimates
Operating expenses and net loss
Stock-based compensation
GAAP operating loss and dilution analysis

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Journey Medical Corp

DERM · Pharmaceutical Preparations

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

: 28.4.2026